UPPSALA, SE / ACCESSWIRE / August 15, 2022 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II)

Biovica, active in cancer diagnostics, is hosting a market update due DiviTum®TKa's US market approval received on July 29 from the US Food and Drug Administration (FDA).

At the update on Thursday 18 August 15.00-16.00 CET, CEO Anders Rylander will give a short introduction. Joakim Arwidsson, VP RA/QA, about the 510(k) clearance, Henrik Winter, SVP Business Development, will describe the clinical application of the test and Warren Cresswell, President Americas, will describe the US Go-to-market plan.

DiviTum®TKa received 510(k) clearance on July 29, 2022, as an aid in monitoring disease progression in previously diagnosed hormone receptor positive, metastatic postmenopausal female breast cancer patients.

Link to the event: Biovica International Market update FDA clearance 2022 (streamfabriken.com)

Contact

Anders Rylander, CEO
Phone: +46-18-444 48 35
E-mail: [email protected]

Biovica - Treatment decisions with greater confidence

Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medical Products Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, [email protected], +46 8 528 00 399. For more information please visit: www.biovica.com.

Attachments

Biovica invites to market update on 18 August 15.00 - Bringing DiviTum®TKa to US patients

SOURCE: Biovica International